Name: Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size, Share, Industry, Forecast and outlook (2023-2030)
Brand: DataM Intelligence
SKU: BT4822
Price: 4350 USD
Availability: InStock

Autologous Stem Cell and Non-Stem Cell Based Therapies Market 2023-30

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is segmented By Type (Autologous Stem Cells,&nbsp;Autologous Non-Stem cells,&nbsp;Others),&nbsp;By Application (Cancer,&nbsp;Neurodegenerative Disorders,&nbsp;Cardiovascular Disease,&nbsp;Orthopedic Diseases,&nbsp;Others),&nbsp;By End-User (Hospitals,&nbsp;Ambulatory Surgical Centers,&nbsp;Research Facilities,&nbsp;Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2023-2030.</h2>

&nbsp;

<h2>Autologous Stem Cell and Non-Stem Cell Based Therapies Market&nbsp;Overview</h2>

<blockquote>
The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market reached USD 6.8 billion in 2022 and is projected to witness lucrative growth by reaching up to USD 18.4 billion by 2030. The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is expected to exhibit a CAGR of 13.7% from 2023 to 2030.
</blockquote>

The growing number of chronic conditions, including neurodegenerative disorders, orthopedic injuries, and cardiovascular diseases, increasing demand for regenerative medicine, research advancements, and increase in market developments such as mergers, acquisitions, collaborations, product introductions, and approvals are among the fundamental elements expected to promote the global autologous stem cell and non-stem cell therapy based therapies market growth in the forecast period.

<h2>&nbsp;</h2>

<h2>Autologous Stem Cell and Non-Stem Cell Based Therapies Market&nbsp; Scope</h2>

<table cellspacing="0" style="border-collapse:collapse; width:624px">
	<tbody>
		<tr>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #4472c4; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Metrics
			</td>
			<td style="background-color:#4472c4; border-bottom:1px solid #4472c4; border-left:1px solid #8eaadb; border-right:1px solid #4472c4; border-top:1px solid #4472c4; vertical-align:top; width:312px">
			Details
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			CAGR
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #4472c4; vertical-align:middle; width:312px">
			13.7%
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Size Available for Years
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2021-2030
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Forecast Period
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			2023-2030
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Data Availability
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Value (US$)
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Segments Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Type, Application, End-user
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Regions Covered
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America, Europe, Asia-Pacific, South America, and Middle East &amp; Africa
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Fastest Growing Region
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Asia-Pacific
			</td>
		</tr>
		<tr>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Largest Region
			</td>
			<td style="background-color:#d6e6f4; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			North America
			</td>
		</tr>
		<tr>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Report Insights Covered
			</td>
			<td style="background-color:#d9e2f3; border-bottom:1px solid #8eaadb; border-left:1px solid #8eaadb; border-right:1px solid #8eaadb; border-top:1px solid #8eaadb; vertical-align:middle; width:312px">
			Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Type Launches, Growth Strategies, Revenue Analysis, Porter&rsquo;s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.
			</td>
		</tr>
	</tbody>
</table>

&nbsp;

<h3>To know more Insights -&nbsp;<a href="https://www.datamintelligence.com/industry-verticals/biotechnology">Dowload Sample</a></h3>

<h2>&nbsp;</h2>

<h2>Autologous Stem Cell and Non-Stem Cell Based Therapies Market&nbsp;Dynamics</h2>

Increasing Market Developments&nbsp; Drive the Growth of&nbsp; the Autologous Stem Cell and Non-Stem Cell Based Therapies Market

The increasing market developments in the autologous stem cell and non-stem cell-based therapies market are expected to boost the market growth in the forecast period. For instance, in May 2022, Sernova, a regenerative treatment corporation, and Evotec, a publicly listed drug discovery and designing corporation, formed a partnership for the creating a cell therapy to be utilized in the treatment of insulin-dependent diabetes employing induced pluripotent stem cells (iPSC)-based therapeutics.

Moreover, in October 2021, the U.S. FDA authorized the usage of the brexucabtagene autoleucel (Tecartus), a CAR-T therapy for patients with B-cell precursor ALL who have not reacted to previous therapy (refractory) or whose disease has returned after treatment.

The Research Funding is Expected To Present The Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market With Growth Opportunities

The increasing research funding is presenting the global market with prospective growth opportunities. For instance, in April 2023, the Board of the California Institute for Regenerative Medicine (CIRM) authorized funding about $89 million in projects from its Clinical and Translation programs at its April meeting.&nbsp;

About $39 million intends to fund four assignments in the agency&rsquo;s clinical program, which quickens the aid and delivers grants for suitable stem cell and gene therapy-based projects via any stage of clinical trial activity.

The High Cost Of Autologous Cell Therapy is Estimated to Hamper the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market During The Forecast Period

The high cost of autologous cell therapy is hampering the growth of global autologous stem cell and non-stem cell-based therapies in the forecast period. For instance, CAR T-cell therapy expense is estimated to be between US$500,000 and US$1,000,000.

For more details on this report - <a href="https://www.datamintelligence.com/download-sample/autologous-stem-cell-and-non-stem-cell-based-therapies-market">Request for Sample</a>

<h2>&nbsp;</h2>

<h2>Autologous Stem Cell and Non-Stem Cell Based Therapies Market&nbsp;Segment Analysis</h2>

The Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market is segmented based on type, application, end-user, and region.

The Cancer Application is Estimated to Dominate the Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market

Owing to the increasing cancer cases worldwide, the cancer application of autologous stem cell and non-stem cell-based therapies is estimated to dominate the global market holding around 39.7% of the worldwide market.&nbsp;

For instance, according to the WHO, cancer is a top reason of death globally, accounting for almost 10 million deaths in 2020. The highly typical new cancer cases in 2020 were breast cancer accounting for 2.26 million cases, lung cancer accounting for 2.21 million cases, colon and rectum making up for 1.93 million cases, and prostate cancer accounting for over 1.41 million cases.

<img src="https://lh6.googleusercontent.com/r3IcG2CEg0ctY1jPFdeRw2gP2gbrapmc8diNsTT5iP8eQIqVK81JQL0dDV1i_ZS0BZI4M6ygpX_Nd8vj53VV6Wn7BXzVVlUDyrlaFxSliD40FINlCUX6RfmQtUKoUanMjgbBQXyyBxO-dhLURe7b2A" style="height:336px; width:576px" />

Source: DataM Intelligence Analysis (2023)

<h2>&nbsp;</h2>

<h2>Global Autologous Stem Cell and Non-Stem Cell Based Therapies Market&nbsp;Geographical Penetration</h2>

North America is Estimated to hold Approximately 41.6% of the Market Share by 2030, Owing to the Increasing Cases of Chronic Conditions.

Due to the increasing chronic disorder cases in this region, North America is estimated to hold around 41.6% of the total Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market share throughout the forecast period.&nbsp;

For instance, the National Cancer Institute, in January 2022, estimated that there were over 18.1 million cancer survivors in the United States, representing around 5.4% of the population. Moreover, according to the American Cancer Society, in 2022, over 1,918,030 new cancer cases and about 609,360 cancer deaths were anticipated to transpire in the United States, including roughly 350 deaths each day from lung cancer, the top reason for cancer death.

<img src="https://lh5.googleusercontent.com/NLHrIXnr_A13CbePuFyKjBayYeffa0vmFb0za1bP7C8BCtfzZ2jYnda1Jae5zeCf1F7WXvu5HODVS0AFhQhSBxxPqcmyN0hQ17YwpBYZuTMBc6b3k5wJvJcetFoxLA6P6BpIgmzuB_eTwkdv7fA3bQ" style="height:336px; width:576px" />

Source: DataM Intelligence Analysis (2023)

<h2>&nbsp;</h2>

<h2>Autologous Stem Cell and Non-Stem Cell Based Therapies Companies</h2>

The major global players in the autologous stem cell and non-stem cell-based therapies market include Novartis AG, BrainStorm Cell Limited, Caladrius, Cytori Therapeutics Inc., Gilead Sciences Inc., Regeneus Ltd, U.S. Stem Cell, Vericel Corporation, MEDIPOST, Castle Creek Biosciences, Inc., among others.

&nbsp;

<h2>COVID-19 Impact on&nbsp;Autologous Stem Cell and Non-Stem Cell Based Therapies Market&nbsp;</h2>

Russia-Ukraine Conflict Analysis

The Russia-Ukraine brawl is considered to have minimal impact on the Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market because of the low prevalence and dearth of critical market players in this region. Yet, persisting to countenance raids from Russian troops, Ukrainian infirmaries are pushed by increasing numerals of deaths and specified medical aids.&nbsp;

There are deficiencies across all kinds of drugs. Again, the consequence of the import and export of basic materials is predicted to have a small influence on the growth of global autologous stem cell and non-stem cell-based therapies in the forecast period.

By Type

<ul>
	<li>Autologous Stem Cells</li>
	<li>Autologous Non-Stem cells</li>
</ul>

By Application

<ul>
	<li>Cancer</li>
	<li>Neurodegenerative Disorders</li>
	<li>Cardiovascular Disease</li>
	<li>Orthopedic Diseases</li>
	<li>Others</li>
</ul>

By End-user

<ul>
	<li>Hospitals</li>
	<li>Specialty Clinics</li>
	<li>Others</li>
</ul>

By Region

<ul>
	<li>North America
	<ul>
		<li>The U.S.</li>
		<li>Canada</li>
		<li>Mexico</li>
	</ul>
	</li>
	<li>Europe
	<ul>
		<li>Germany</li>
		<li>The U.K.</li>
		<li>France</li>
		<li>Spain</li>
		<li>Italy</li>
		<li>Rest of Europe</li>
	</ul>
	</li>
	<li>South America
	<ul>
		<li>Brazil</li>
		<li>Argentina</li>
		<li>Rest of South America</li>
	</ul>
	</li>
	<li>Asia-Pacific
	<ul>
		<li>China</li>
		<li>India</li>
		<li>Japan</li>
		<li>Australia</li>
		<li>Rest of Asia-Pacific</li>
	</ul>
	</li>
	<li>Middle East and Africa</li>
</ul>

<h2>Key Developments</h2>

<ul>
	<li>In June 2022 cell therapy developer Tessa Therapeutics disclosed a $126M Series A round of grant to invest in continued clinical development of two additional kinds of cancer therapies. TT11 is the Singapore-based corporation&rsquo;s autologous cell therapy, which is produced from a patient&rsquo;s T cells. That cell therapy nominee targets the cancer protein CD30 and is being prepared to start a pivotal Phase 2 test later this year.</li>
	<li>In April 2022, Metcela, a clinical-stage biotech startup completed the acquisition of Japan Regenerative Medicine Co. Ltd to design cardiac stem cell-based therapy. Via the investment, Metcela is expected to add an autologous cell development for a pediatric congenital heart condition to its pipeline and greatly amplify its clinical development infrastructure for regenerative medicine developments.</li>
	<li>In December 2021, Novartis introduced its T-Charge, the corporation&rsquo;s next-generation CAR-T platform that intends to function as the foundation for diverse new investigational CAR-T cell therapies in the Novartis pipeline.</li>
</ul>

Why Purchase the Report?

<ul>
	<li>To visualize the Global Autologous Stem Cell and Non-Stem Cell-Based Therapies Market segmentation based on type, application, end-user, and region, as well as understand key commercial assets and players.</li>
	<li>Identify commercial opportunities by analyzing trends and co-development.&nbsp;</li>
	<li>Excel data sheet with numerous data points of autologous stem cell and non-stem cell-based therapies market-level with all segments.</li>
	<li>PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.</li>
	<li>Type mapping available in Excel consisting of key types of all the major players.</li>
</ul>

The Global Autologous Stem Cell And Non-Stem Cell-Based Therapies Market Report Would Provide Approximately 53 Tables, 54 Figures And 195 Pages.

Target Audience 2023

<ul>
	<li>Manufacturers/ Buyers</li>
	<li>Industry Investors/Investment Bankers</li>
	<li>Research Professionals</li>
	<li>Emerging Companies</li>
</ul>

<ol>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Methodology and Scope</h3>

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Definition and Overview</h3>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Executive Summary</h3>

	<ol>
		<li>Snippet by Type</li>
		<li>Snippet by Application</li>
		<li>Snippet by End-user</li>
		<li>Snippet by Region</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Dynamics</h3>

	<ol>
		<li>Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing Market Developments</li>
				<li>Growing Prevalence of Chronic Conditions</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>High Cost</li>
			</ol>
			</li>
			<li>Opportunity
			<ol>
				<li>Increasing Fundings</li>
			</ol>
			</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Industry Analysis&nbsp;</h3>

	<ol>
		<li>Porter&rsquo;s 5 Forces Analysis&nbsp;&nbsp;</li>
		<li>Supply Chain Analysis</li>
		<li>Pricing Analysis</li>
		<li>Regulatory Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">COVID-19 Analysis</h3>

	<ol>
		<li>Analysis of COVID-19
		<ol>
			<li>Scenario Before COVID-19</li>
			<li>Scenario During COVID-19</li>
			<li>Scenario Post COVID-19</li>
		</ol>
		</li>
		<li>Pricing Dynamics Amid COVID-19</li>
		<li>Demand-Supply Spectrum</li>
		<li>Government Initiatives Related to the Market During the Pandemic</li>
		<li>Manufacturers Strategic Initiatives</li>
		<li>Conclusion</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Type</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Attractiveness Index, By Type</li>
		</ol>
		</li>
		<li>Autologous Stem Cells *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Autologous Non-Stem cells</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Application</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Attractiveness Index, By Application</li>
		</ol>
		</li>
		<li>Cancer*
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Neurodegenerative Disorders</li>
		<li>Cardiovascular Disease</li>
		<li>Orthopedic Diseases</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By End-user</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user</li>
			<li>Market Attractiveness Index, By End-user</li>
		</ol>
		</li>
		<li>Hospitals *
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%)</li>
		</ol>
		</li>
		<li>Specialty Clinics</li>
		<li>Others</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">By Region</h3>

	<ol>
		<li>Introduction
		<ol>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>The U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>The U.K.</li>
				<li>France</li>
				<li>Spain</li>
				<li>Italy</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia-Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user&nbsp;</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Rest of Asia-Pacific&nbsp;</li>
		<li>Middle East and Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Type</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By Application</li>
			<li>Market Size Analysis and Y-o-Y Growth Analysis (%), By End-user&nbsp;&nbsp;</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Competitive Landscape</h3>

	<ol>
		<li>Competitive Scenario</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Company Profiles</h3>

	<ol>
		<li>MEDIPOST *
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Financial Overview</li>
			<li>Key Developments</li>
		</ol>
		</li>
		<li>Novartis AG</li>
		<li>BrainStorm Cell Limited</li>
		<li>Caladrius</li>
		<li>Cytori Therapeutics Inc.</li>
		<li>Gilead Sciences Inc.</li>
		<li>Regeneus Ltd</li>
		<li>U.S. Stem Cell, Inc</li>
		<li>Vericel Corporation</li>
		<li>Castle Creek Biosciences, Inc.(*LIST NOT EXHAUSTIVE)&nbsp;</li>
	</ol>
	</li>
	<li>
	<h3 style="color:#1f3863; font-style:normal">Appendix</h3>

	<ol>
		<li>About Us and Services</li>
		<li>Contact Us</li>
	</ol>
	</li>
</ol>

<h3>List of Tables</h3>

Table 1 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2022, 2026 &amp; 2030 (US$ Billion)

Table 2 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2022, 2026 &amp; 2030 (US$ Billion)

Table 3 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2022, 2026 &amp; 2030 (US$ Billion)

Table 4 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Billion)

Table 5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2022, 2026 &amp; 2030 (US$ Billion)

Table 6 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2021-2030 (US$ Billion)

Table 7 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2022, 2026 &amp; 2030 (US$ Billion)

Table 8 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2021-2030 (US$ Billion)

Table 9 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2022, 2026 &amp; 2030 (US$ Billion)

Table 10 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2021-2030 (US$ Billion)

Table 11 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Region, 2022, 2026 &amp; 2030 (US$ Billion)

Table 12 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Region, 2021-2030 (US$ Billion)

Table 13 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2021-2030 (US$ Billion)

Table 14 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2021-2030 (US$ Billion)

Table 15 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2021-2030 (US$ Billion)

Table 16 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Country, 2021-2030 (US$ Billion)

Table 17 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2021-2030 (US$ Billion)

Table 18 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2021-2030 (US$ Billion)

Table 19 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2021-2030 (US$ Billion)

Table 20 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Country, 2021-2030 (US$ Billion)

Table 21 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2021-2030 (US$ Billion)

Table 22 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2021-2030 (US$ Billion)

Table 23 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2021-2030 (US$ Billion)

Table 24 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Country, 2021-2030 (US$ Billion)

Table 25 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Country, 2021-2030 (US$ Billion)

Table 29 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Type, 2021-2030 (US$ Billion)

Table 30 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By Application, 2021-2030 (US$ Billion)

Table 31 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, By End User, 2021-2030 (US$ Billion)

Table 32 MEDIPOST: Overview

Table 33 MEDIPOST: Product Portfolio

Table 34 MEDIPOST: Key Developments

Table 35 Novartis AG: Overview

Table 36 Novartis AG: Product Portfolio

Table 37 Novartis AG: Key Developments

Table 38 BrainStorm Cell Limited: Overview

Table 39 BrainStorm Cell Limited: Product Portfolio

Table 40 BrainStorm Cell Limited: Key Developments

Table 41 Caladrius: Overview

Table 42 Caladrius: Product Portfolio

Table 43 Caladrius: Key Developments

Table 44 Cytori Therapeutics Inc.: Overview

Table 45 Cytori Therapeutics Inc.: Product Portfolio

Table 46 Cytori Therapeutics Inc.: Key Developments

Table 47 Gilead Sciences Inc.: Overview

Table 48 Gilead Sciences Inc.: Product Portfolio

Table 49 Gilead Sciences Inc.: Key Developments

Table 50 Regeneus Ltd: Overview

Table 51 Regeneus Ltd: Product Portfolio

Table 52 Regeneus Ltd: Key Developments

Table 53 U.S. Stem Cell, Inc: Overview

Table 54 U.S. Stem Cell, Inc: Product Portfolio

Table 55 U.S. Stem Cell, Inc: Key Developments

Table 56 Vericel Corporation: Overview

Table 57 Vericel Corporation: Product Portfolio

Table 58 Vericel Corporation: Key Developments

Table 59 Castle Creek Biosciences, Inc.: Overview

Table 60 Castle Creek Biosciences, Inc.: Product Portfolio

Table 61 Castle Creek Biosciences, Inc.: Key Developments

<h3>List of Figures</h3>

Figure 1 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Type, 2022 &amp; 2030 (%)

Figure 3 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Application, 2022 &amp; 2030 (%)

Figure 4 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By End User, 2022 &amp; 2030 (%)

Figure 5 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Region, 2022 &amp; 2030 (%)

Figure 6 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Y-o-Y Growth, By Type, 2022-2030 (%)

Figure 7 Autologous Stem Cells Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 8 Autologous Non-Stem Cells Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 9 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Y-o-Y Growth, By Application, 2022-2030 (%)

Figure 10 Cancer Application in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 11 Neurodegenerative Disorders Application in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 12 Cardiovascular Disease Application in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 13 Orthopedic Diseases Application in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 14 Others Application in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 15 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Y-o-Y Growth, By End User, 2022-2030 (%)

Figure 16 Hospitals End User in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 17 Specialty Clinics End User in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 18 Other End Users in Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 19 Global Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 21 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 22 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 23 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 24 Middle East and Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 25 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 26 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Type, 2022 &amp; 2030 (%)

Figure 27 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Application, 2022 &amp; 2030 (%)

Figure 28 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By End User, 2022 &amp; 2030 (%)

Figure 29 North America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Country, 2022 &amp; 2030 (%)

Figure 30 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 31 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Type, 2022 &amp; 2030 (%)

Figure 32 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Application, 2022 &amp; 2030 (%)

Figure 33 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By End User, 2022 &amp; 2030 (%)

Figure 34 South America Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Country, 2022 &amp; 2030 (%)

Figure 35 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 36 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Type, 2022 &amp; 2030 (%)

Figure 37 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Application, 2022 &amp; 2030 (%)

Figure 38 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By End User, 2022 &amp; 2030 (%)

Figure 39 Europe Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Country, 2022 &amp; 2030 (%)

Figure 40 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 41 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Type, 2022 &amp; 2030 (%)

Figure 42 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Application, 2022 &amp; 2030 (%)

Figure 43 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By End User, 2022 &amp; 2030 (%)

Figure 44 Asia-Pacific Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Country, 2022 &amp; 2030 (%)

Figure 45 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Value, 2021-2030 (US$ Billion)

Figure 46 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Type, 2022 &amp; 2030 (%)

Figure 47 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By Application, 2022 &amp; 2030 (%)

Figure 48 Middle East &amp; Africa Autologous Stem Cell and Non-Stem Cell Based Therapies&nbsp;Market Share, By End User, 2022 &amp; 2030 (%)

Figure 49 MEDIPOST: Financials

Figure 50 Novartis AG: Financials

Figure 51 BrainStorm Cell Limited: Financials

Figure 52 Caladrius: Financials

Figure 53 Cytori Therapeutics Inc.: Financials

Figure 54 Gilead Sciences Inc.: Financials

Figure 55 Regeneus Ltd: Financials

Figure 56 U.S. Stem Cell, Inc: Financials

Figure 57 Vericel Corporation: Financials

Figure 58 Castle Creek Biosciences, Inc.: Financials

Autologous Stem Cell and Non-Stem Cell Based Therapies Market Size, Share, Industry, Forecast and outlook (2023-2030)

Allogeneic Stem Cells Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 September 21

Starting from

Antibody Drug Conjugates Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 November 24

Starting from

Monoclonal Antibody Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 August 25

Starting from

Next Generation Antibody Therapeutics Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 October 05

Starting from

Custom Antibody Services Market Size, Share, Industry, Forecast and Outlook (2023-2030)

Published: 2023 October 31

Starting from

Animal Stem Cell Therapy Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 09

Starting from